Pliant Therapeutics Inc. (PLRX) Appoints Katharine Knobil to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
September 15, 2022 8:00 AM EDTSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately.
I would like to extend a warm welcome to Kate whose global clinical development and strategic leadership experience, including her training as a pulmonologist, aligns perfectly with Pliant as we evolve into a late-stage biotechnology company, said Bernard Coulie, M.D., Ph.D., President and Chief Executive... More
